Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:54
07/06/21
07/06
08:54
07/06/21
08:54
ISEE

Iveric bio

$7.92 /

+0.88 (+12.50%)

, CANO

Cano Health

$12.04 /

+0.275 (+2.34%)

, MNOV

MediciNova

$4.12 /

-0.045 (-1.08%)

, AXLA

Axcella Health

$3.95 /

-0.04 (-1.00%)

, OCGN

Ocugen

$7.30 /

-0.54 (-6.89%)

, BLIN

Bridgeline Digital

$8.92 /

+3.19 (+55.67%)

, DIDI

DiDi

$15.53 /

-0.81 (-4.96%)

, YMM

Full Truck Alliance

$18.99 /

+0.45 (+2.43%)

, BZ

Kanzhun

$36.32 /

-0.94 (-2.52%)

, PRVB

Provention Bio

$8.29 /

-0.03 (-0.36%)

, AHT

Ashford Hospitality

$3.97 /

-0.375 (-8.64%)

Check out this morning's…

ShowHide Related Items >><<
YMM Full Truck Alliance
$18.99 /

+0.45 (+2.43%)

PRVB Provention Bio
$8.29 /

-0.03 (-0.36%)

OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

ISEE Iveric bio
$7.92 /

+0.88 (+12.50%)

DIDI DiDi
$15.53 /

-0.81 (-4.96%)

CANO Cano Health
$12.04 /

+0.275 (+2.34%)

BZ Kanzhun
$36.32 /

-0.94 (-2.52%)

BLIN Bridgeline Digital
$8.92 /

+3.19 (+55.67%)

AXLA Axcella Health
$3.95 /

-0.04 (-1.00%)

AHT Ashford Hospitality
$3.97 /

-0.375 (-8.64%)

ISEE Iveric bio
$7.92 /

+0.88 (+12.50%)

08/13/20 Credit Suisse
Iveric bio initiated with an Outperform at Credit Suisse
CANO Cano Health
$12.04 /

+0.275 (+2.34%)

11/19/20 Compass Point
Compass Point upgrades PennantPark to Buy after Cano Health 'game changer'
MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
AXLA Axcella Health
$3.95 /

-0.04 (-1.00%)

07/06/21 H.C. Wainwright
Axcella Health initiated with a Buy at H.C. Wainwright
06/03/21 Chardan
Axcella Health price target raised to $16 from $10 at Chardan
04/13/21 Piper Sandler
Piper says IND clearance sets up Axcella Health for potential NASH 'home run'
03/22/21 Wedbush
Axcella Health price target lowered to $11 from $19 at Wedbush
OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
06/10/21 Roth Capital
Ocugen downgraded to Neutral from Buy at Roth Capital
06/10/21 Chardan
Ocugen price target lowered to $4.50 from $8 at Chardan
BLIN Bridgeline Digital
$8.92 /

+3.19 (+55.67%)

DIDI DiDi
$15.53 /

-0.81 (-4.96%)

YMM Full Truck Alliance
$18.99 /

+0.45 (+2.43%)

BZ Kanzhun
$36.32 /

-0.94 (-2.52%)

PRVB Provention Bio
$8.29 /

-0.03 (-0.36%)

05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
05/07/21 Cantor Fitzgerald
Provention Bio price target lowered to $19 from $25 at Cantor Fitzgerald
04/12/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
AHT Ashford Hospitality
$3.97 /

-0.375 (-8.64%)

06/15/21 B. Riley
Ashford Hospitality price target raised to $5 from $3 at B. Riley
02/01/21 B. Riley
Ashford Hospitality price target raised to $3 from $2.50 at B. Riley Securities
12/02/20 B. Riley
Ashford Hospitality price target lowered to $2.50 from $3.50 at B. Riley
11/16/20 B. Riley
Ashford Hospitality price target lowered to $3.50 from $5 at B. Riley Securities
PRVB Provention Bio
$8.29 /

-0.03 (-0.36%)

OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

ISEE Iveric bio
$7.92 /

+0.88 (+12.50%)

CANO Cano Health
$12.04 /

+0.275 (+2.34%)

AXLA Axcella Health
$3.95 /

-0.04 (-1.00%)

  • 30
    Jun
  • 22
    Jun
  • 11
    Jun
  • 14
    Jan
OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

DIDI DiDi
$15.53 /

-0.81 (-4.96%)

YMM Full Truck Alliance
$18.99 /

+0.45 (+2.43%)

PRVB Provention Bio
$8.29 /

-0.03 (-0.36%)

OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

DIDI DiDi
$15.53 /

-0.81 (-4.96%)

CANO Cano Health
$12.04 /

+0.275 (+2.34%)

BZ Kanzhun
$36.32 /

-0.94 (-2.52%)

AHT Ashford Hospitality
$3.97 /

-0.375 (-8.64%)

PRVB Provention Bio
$8.29 /

-0.03 (-0.36%)

OCGN Ocugen
$7.30 /

-0.54 (-6.89%)

CANO Cano Health
$12.04 /

+0.275 (+2.34%)

AXLA Axcella Health
$3.95 /

-0.04 (-1.00%)

AHT Ashford Hospitality
$3.97 /

-0.375 (-8.64%)

Hot Stocks
MediciNova receives notice of allowance for patent covering MN-166 » 06:31
07/06/21
07/06
06:31
07/06/21
06:31
MNOV

MediciNova

$4.12 /

-0.045 (-1.08%)

MediciNova announced that…

MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of ophthalmic disease. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039. The allowed claims cover methods of treating an ophthalmic disease/disorder or injury associated with a neurodegenerative disease/disorder or a neuro-ophthalmologic disorder by administering to a human patient a therapeutically effective amount of MN-166 (ibudilast). The allowed claims specifically cover the treatment of macular injury. The allowed claims cover a wide range of doses and formulations of MN-166 (ibudilast) and a range of different dosing frequencies.

ShowHide Related Items >><<
MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$4.12 /

-0.045 (-1.08%)

Over a month ago
Hot Stocks
MediciNova to conduct mouse study to develop MN-166 » 06:35
06/28/21
06/28
06:35
06/28/21
06:35
MNOV

MediciNova

$4.16 /

+0.19 (+4.79%)

MediciNova announced it…

MediciNova announced it will conduct a mouse study to investigate the efficacy of MN-166 in a murine model of chlorine-induced lung injury and lethality. After mice are exposed to chlorine gas and treated with MN-166 or control, the study will evaluate survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histopathology. This mouse study and the sheep study announced recently are the result of a partnership between MediciNova and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.

ShowHide Related Items >><<
MNOV MediciNova
$4.16 /

+0.19 (+4.79%)

MNOV MediciNova
$4.16 /

+0.19 (+4.79%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$4.16 /

+0.19 (+4.79%)

Conference/Events
MediciNova participates in a conference call with Maxim » 12:25
06/23/21
06/23
12:25
06/23/21
12:25
MNOV

MediciNova

$3.89 /

-0.085 (-2.14%)

Healthcare Analyst…

Healthcare Analyst McCarthy holds a conference call with CEO Iwaki and VP O'Brien will be held on June 23 at 1 pm hosted by Maxim.

ShowHide Related Items >><<
MNOV MediciNova
$3.89 /

-0.085 (-2.14%)

MNOV MediciNova
$3.89 /

-0.085 (-2.14%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$3.89 /

-0.085 (-2.14%)

Conference/Events
MediciNova participates in a conference call with Maxim » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
MNOV

MediciNova

$4.02 /

-0.165 (-3.95%)

Healthcare Analyst…

Healthcare Analyst McCarthy holds a conference call with CEO Iwaki and VP O'Brien will be held on June 23 at 1 pm hosted by Maxim.

ShowHide Related Items >><<
MNOV MediciNova
$4.02 /

-0.165 (-3.95%)

MNOV MediciNova
$4.02 /

-0.165 (-3.95%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$4.02 /

-0.165 (-3.95%)

On The Fly
Fly Intel: Pre-market Movers » 09:12
06/21/21
06/21
09:12
06/21/21
09:12
RAVN

Raven

$38.58 /

-2.18 (-5.35%)

, CNHI

CNH Industrial

$16.20 /

-0.57 (-3.40%)

, MNOV

MediciNova

$3.77 /

-0.04 (-1.05%)

, ENOB

Enochian Biosciences

$5.78 /

-0.13 (-2.20%)

, TRCH

Torchlight Energy Resources

$6.26 /

+0.875 (+16.25%)

, ALLO

Allogene Therapeutics

$24.47 /

-0.21 (-0.85%)

, TBPH

Theravance Biopharma

$17.50 /

-0.09 (-0.51%)

, IMMP

Immutep

$4.70 /

+ (+0.00%)

, RIOT

Riot Blockchain

$32.18 /

-2.07 (-6.04%)

, MARA

Marathon Digital

$28.92 /

-1.09 (-3.63%)

, COIN

Coinbase

$229.47 /

-0.87 (-0.38%)

Check out this morning's…

ShowHide Related Items >><<
TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

05/18/21 Lake Street
Raven price target raised to $55 from $50
03/19/21 Lake Street
Raven initiated with a Buy at Lake Street
CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

05/12/21 Evercore ISI
CNH Industrial price target raised to $25 from $18 at Evercore ISI
05/07/21 BofA
CNH Industrial added to US 1 List at BofA
04/23/21 AlphaValue
CNH Industrial upgraded to Add from Sell at AlphaValue
04/13/21 Deutsche Bank
CNH Industrial price target raised to $21 from $18 at Deutsche Bank
MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

03/09/21 SVB Leerink
Theravance Biopharma sum-of-the-parts may be worth $78/share, says SVB Leerink
02/24/21 SVB Leerink
Theravance Biopharma price target raised to $41 from $35 at SVB Leerink
11/23/20 Evercore ISI
Theravance Biopharma resumed with an Outperform at Evercore ISI
10/14/20 Morgan Stanley
Morgan Stanley upgrades Theravance Biopharma to Overweight following pullback
IMMP Immutep
$4.70 /

+ (+0.00%)

06/10/21 Alliance Global Partners
Immutep price target raised to $9 from $6 at Alliance Global Partners
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
01/26/21 Alliance Global Partners
Immutep price target raised to $6 from $5 at Alliance Global Partners
12/14/20 Maxim
Maxim doubled Immutep price target after breast cancer update
RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

06/21/21 Compass Point
Compass Point starts Riot Blockchain at Buy after 'transformational' deal
06/21/21 Compass Point
Riot Blockchain initiated with a Buy at Compass Point
06/01/21 B. Riley
Riot Blockchain deal closing 'major positive' for shares, says B. Riley
06/01/21 H.C. Wainwright
Riot Blockchain price target raised to $40 from $30 at H.C. Wainwright
MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

06/21/21 Compass Point
Compass sees Marathon Digital becoming largest bitcoin miner, starts at Buy
06/21/21 Compass Point
Marathon Digital initiated with a Buy at Compass Point
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 B. Riley
Marathon Digital initiated with a Buy, $47 target at B. Riley
COIN Coinbase
$229.47 /

-0.87 (-0.38%)

06/16/21
Fly Intel: Top five analyst initiations
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/08/21 Raymond James
Raymond James starts Coinbase at Underperform, sees fee compression coming
TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

  • 14
    Apr
  • 08
    Feb
  • 24
    Jul
TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

Hot Stocks
MediciNova announces publication of results from Phase 2 trial of MN-166 » 06:33
06/21/21
06/21
06:33
06/21/21
06:33
MNOV

MediciNova

$3.77 /

-0.04 (-1.05%)

MediciNova announced that…

MediciNova announced that results from a Phase 2 trial of MN-166 in alcohol use disorder were published in Nature's Translational Psychiatry. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California at Los Angeles and was funded by the Center for Study of Opioid Receptors and Drugs of Abuse. This study was a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 AUD patients were enrolled in this trial. The publication, entitled "Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial" was authored by Dr. Lara Ray and colleagues at UCLA. Key results reported in the publication include the following: Ibudilast did not have a significant effect on negative mood. Ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45%. Ibudilast attenuated alcohol cue-elicited activation in the ventral striatum compared to placebo. Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group, such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. Ibudilast reduced alcohol craving compared to placebo on non-drinking days. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.

ShowHide Related Items >><<
MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

Conference/Events
MediciNova participates in a conference call with Maxim » 14:41
06/15/21
06/15
14:41
06/15/21
14:41
MNOV

MediciNova

$4.09 /

-0.13 (-3.08%)

Healthcare Analyst…

Healthcare Analyst McCarthy holds a conference call with CEO Iwaki and VP O'Brien will be held on June 23 at 1 pm hosted by Maxim.

ShowHide Related Items >><<
MNOV MediciNova
$4.09 /

-0.13 (-3.08%)

MNOV MediciNova
$4.09 /

-0.13 (-3.08%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$4.09 /

-0.13 (-3.08%)

Hot Stocks
MediciNova initiates sheep study to investigate MN-166 » 06:44
06/07/21
06/07
06:44
06/07/21
06:44
MNOV

MediciNova

$4.07 /

-0.02 (-0.49%)

MediciNova announced it…

MediciNova announced it has initiated a sheep study to investigate MN-166 in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 or control, the study will evaluate pulmonary function, lung injury and edema formation, cardiopulmonary hemodynamics, and systemic vascular permeability. MediciNova has partnered with the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority.

ShowHide Related Items >><<
MNOV MediciNova
$4.07 /

-0.02 (-0.49%)

MNOV MediciNova
$4.07 /

-0.02 (-0.49%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$4.07 /

-0.02 (-0.49%)

Over a quarter ago
Hot Stocks
MediciNova receives two milestone payments from Sanofi subsidiary for $4M » 06:59
04/22/21
04/22
06:59
04/22/21
06:59
MNOV

MediciNova

$4.52 /

+0.13 (+2.96%)

, SNY

Sanofi

$52.43 /

+0.44 (+0.85%)

MediciNova (MNOV) has…

MediciNova (MNOV) has received two milestone payments under MediciNova's assignment agreement with Genzyme, a subsidiary of Sanofi (SNY). The milestone payments, which total $4M, are a result of the successful achievement of two clinical development milestones for a gene therapy product based on adeno-associated virus vector technology that is covered under the assignment agreement.

ShowHide Related Items >><<
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

MNOV MediciNova
$4.52 /

+0.13 (+2.96%)

MNOV MediciNova
$4.52 /

+0.13 (+2.96%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

MNOV MediciNova
$4.52 /

+0.13 (+2.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.